Exalpha Biologicals, Inc.

Accelerating the Pace of Discovery

Product Highlight

Mouse anti-M13 phage coat protein g8p

Antibodies recognising M13 filamentous phage coat proteins are instrumental in the selection and detection of phages expressing specific antibody fragments or peptide sequences at their surface. The monoclonal antibodies manufactured and supplied by Exalpha react with either the pIII (g3p) or pVIII (g8p) proteins of M13 filamentous bacteriophage. All antibodies are available in a purified format. The antibodies are fully validated and are suitable for a wide range of techniques including:

  • ELISA
  • Flow Cytometry
  • Western Blot
  • Immunohistochemistry
  • Immunoprecipitation
For more information, click here for our M13 Bacteriophage information page.

News

Two more of our excellent products have been published by PubMed:

Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis
Borazanci, E., et al., J. Gastrointest. Oncol., 8, 164-172 (2017)
Using Exalpha SPARC Antibody (Cat. No. X1867P)

Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells
Steen, N.V., et al., Am. J. Cancer Res., 7, 816-830 (2017)
Using Exalpha's FITC labeled anti PY20 Antibody (Cat. No. X1017)

Exalpha Biologicals, Inc.

Cycloscope B-All

  • Product Code: 7043
  • Size: 20 Tests
  • Availability: In Stock In Stock
  • Price (USD): $682

Cat #

7043		 Quantity:      

Data Sheet

Product Name

Cycloscope B-All

Product Type

Flow Cytometry Kits

Applications

Flow Cytometry

Size

20 Tests

Price (USD)

$682

Background

Cycloscope B-ALL, is a kit used for the flow cytometric analysis of DNA cell contents in B-lineage acute lymphoblastic leukemia (B-ALL). This kit is mainly focused for DNA studies of leukemic blast cells from bone marrow samples of these patients. Introduction: Acute lymphoblastic leukemia is a disorder characterized by a clonal expansion of lymphoid progenitor cells arrested at different differentation steps whose progressive accumulation causes bone marrow involvement with more than 30% blast cells at diagnosis. According to the European Group for the Immunological Clasification of Leukemias, assignement of an ALL to the B-lineage is based on the expression on leukemic cells of at least two B lineage associated antigens: CD19, cytoplasmic CD79a (mb-1) or cytoplasmic CD22. DNA cell content studies by flow cytometry provide relevant information for the prognostic evaluation and follow-up of patients with acute lymphoblastic leukemia. Detection of hyperdiploid leukemic blast cells is an independent prognostic factor strongly associated with favourable clinical and biologic features (1-3); in addition it may be of great utility for the detection of minimal residual disease contributing to relapse prediction in these patients (4, 5). At present the clinical utility of cell cycle studies in B-lineage ALL still remains to be established (6).

Customer Storage

Product should be stored at 4-8°C. DO NOT FREEZE

References

1. Trueworthy R, Shuster J, Look AT, Crist WM, Borowitz M, Carroll A, Frankel L, Harris M, Wagner H, Haggard M, Mosijczuk A, Pullen J, Steuber P, Land V. Ploidy of lymphoblast is the stronger predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a pediatric oncology group study. J Clin Oncol 10: 606-613; 1992.

2. Pui CH, Raimondi SC, Dodge R, Rivera GK, Fuchs LAH, Abromowitch M, Look AT, Furman WL, Crist WM, Williams D. Prognostic importance of structural chromosomal abnormalities in children with hyperdiploid (>50 chromosomes) acute lymphoblastic leukemia. Blood, 73: 1963-67; 1989.

3. Pui CH, Dodge RK, Look AT, George SL, Rivera GK, Abromowitch M, Ochs J, Evans WE, Crist WM, Simone JV. Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St. Jude total therapy studies VIII, IX and X. Clin. Oncol. 9: 1341; 1991.

4. Nowak R, Oelschlägel U, Hofmann R, Zengler H, Huhn R. Detection of aneuploid cells in acute lymphoblastic leukemia with flow cytometry before and after therapy. Leuk. Res. 18: 897-901; 1989.

5. Ciudad J, San Miguel JF, López-Berges MC, Valverde B, Vidriales B, López AMA, González M, GarcíaSanz R, Orfao A. Immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. In Acute leukemias VI. Prognosis factors and treatment strategies. Büchner et al (eds). Springer-Verlag Berlin Heidelberg 1997.

6. Look AT, Melvin SL, Williams DL, Brodeur GM, Dahl GV, Kalwinsky DK, Murphy SB, Mauer AM. Aneuploidy and percentage of S-phase cells determined by flow cytometry correlate with cell phenotype in childhood acute leukemia. Blood 60: 959-967; 1982.

7. Kaspers GJL, Smets LA, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman AJP. Favorable Prognosis of Hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood 85: 751-756; 1995.


8-.Nygaard U, Larsen J, Kristensen TD, Wesenberg F, Jonsson OG, Carlsen NT, Forestier E, Kirchhoff M, Larsen JK, Schmiegelow K, Christensen IJ. Flow cytometric DNA index, G-band karyotyping, and comparative genomic hybridization in detection of high hyperdiploidy in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol: 28:134-40 (2006).

9-.Shman TV, Savitski VP, Fedasenka UU, Aleinikova OV. Apoptosis and proliferation differences between CD34+ and CD34- leukemic subpopulations in childhood acute leukemia. Hematology. 2:1 (2007).

10-.Heerema NA, Raimondi SC, Anderson JR, Biegel J, Camitta BM, Cooley LD, Gaynon PS, Hirsch B, Magenis RE, McGavran L, Patil S, Pettenati MJ, Pullen J, Rao K, Roulston D, Schneider NR, Shuster JJ, Sanger W, Sutcliffe MJ, van Tuinen P, Watson MS, Carroll AJ. Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemia.Genes Chromosomes Cancer.46:684-93 (2007).